Marshall Wace LLP Grows Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Marshall Wace LLP boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 1,530.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,786 shares of the medical instruments supplier's stock after purchasing an additional 37,346 shares during the period. Marshall Wace LLP owned about 0.18% of LeMaitre Vascular worth $3,666,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its holdings in LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 293 shares during the period. CBIZ Investment Advisory Services LLC raised its stake in LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 117 shares during the period. KBC Group NV lifted its holdings in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after purchasing an additional 410 shares in the last quarter. Huntington National Bank lifted its stake in shares of LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after buying an additional 455 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in LeMaitre Vascular during the 4th quarter valued at about $150,000. Institutional investors and hedge funds own 84.64% of the company's stock.

Insider Activity

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Trading Up 0.6 %

Shares of NASDAQ:LMAT traded up $0.51 during trading on Thursday, reaching $91.25. The company had a trading volume of 61,620 shares, compared to its average volume of 161,360. The company has a fifty day moving average of $86.32 and a two-hundred day moving average of $93.43. The stock has a market capitalization of $2.06 billion, a P/E ratio of 49.91, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $64.80 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts' consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. As a group, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.88%. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 13th. LeMaitre Vascular's payout ratio is presently 41.24%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LMAT. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $98.14.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.